Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry-results+publication

MEEI sudden deafness steroid treatment trial

Also known as: Methylprednisolone sodium succinate, Intratympanic methylprednisolone, Sudden Deafness Treatment Trial, SSNHL trial, NCT00097448

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Steroid/Anti-inflammatory

Stage

Phase 3

Status

Completed

Target Gene

—

Route / Mode

Intratympanic injection; oral prednisone comparator

Confidence

88%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, sudden, sensorineural, unilateral

Trial IDs

Mechanism

Completed multicenter Phase 3 non-inferiority trial comparing intratympanic methylprednisolone sodium succinate injections with oral prednisone for idiopathic sudden sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Corrected from a generic methylprednisolone product row to the completed MEEI/NIDCD sudden-deafness steroid treatment trial. The registry and JAMA publication describe one study comparing oral prednisone with intratympanic methylprednisolone; this is a historical institution-led clinical study, not a commercial methylprednisolone program.

Evidence & Sources

3 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT00097448

Open

publication

Supports: status, mechanism, notes, keyEvents

IDs: PMID:21610239

Open

publication

Supports: notes, keyEvents